Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (9016)
All Articles published online
|
Publishing Process of This Article
|
Dec 27, 2019 (publication date) through Feb 14, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Kutney K, Donnola SB, Flask CA, Gubitosi-Klug R, O’Riordan M, McBennett K, Sferra TJ, Kaminski B. Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients. World J Hepatol 2019; 11(12): 761-772 [PMID: PMC6960296 DOI: 10.4254/wjh.v11.i12.761] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v11/i12/761.htm |
| Number | Citing Articles |
| 1 |
Tanvi Patel, Kimberly McBennett, Senthilkumar Sankararaman, Teresa Schindler, Krithika Sundaram, Nori Mercuri Minich, Sindhoosha Malay, Katherine Kutney. Impact of elexacaftor/tezacaftor/ivacaftor on lipid and fat‐soluble vitamin levels and association with body mass index. Pediatric Pulmonology 2024; 59(3): 734 doi: 10.1002/ppul.26823
|
| 2 |
Rosara Bass, Jessica A. Alvarez. Nutritional status in the era of highly effective CFTR modulators. Pediatric Pulmonology 2024; 59(S1) doi: 10.1002/ppul.26806
|
| 3 |
Julia Konrad, Ernst Eber, Vanessa Stadlbauer. Changing paradigms in the treatment of gastrointestinal complications of cystic fibrosis in the era of cystic fibrosis transmembrane conductance regulator modulators. Paediatric Respiratory Reviews 2022; 42: 9 doi: 10.1016/j.prrv.2020.12.001
|
| 4 |
Lucile Regard, Clémence Martin, Jennifer Da Silva, Pierre-Régis Burgel. CFTR Modulators: Current Status and Evolving Knowledge. Seminars in Respiratory and Critical Care Medicine 2023; 44(02): 186 doi: 10.1055/s-0042-1758851
|
| 5 |
Aikaterini Kanavaki, Ino Kanavaki, Pavlos S. Zoumpoulis, Maria Moustaki, Konstantinos Douros, Ioanna Loukou. Changes in Shear Wave Elastography after Lumacaftor/Ivacaftor Treatment
in Children with Cystic Fibrosis. Current Drug Safety 2023; 18(1): 93 doi: 10.2174/1574886317666220513105114
|
| 6 |
Kimberly McBennett, Christina J. MacAskill, Elise Keshock, Maryam Ghadimi Mahani, Jaime Mata, Alexander J. Towbin, Senthilkumar Sankararaman, Mitchell L. Drumm, Xin Yu, Clement L. Ren, Samya Z. Nasr, Katherine Kutney, Chris A. Flask. Magnetic resonance imaging of cystic fibrosis: Multi-organ imaging in the age of CFTR modulator therapies. Journal of Cystic Fibrosis 2022; 21(2): e148 doi: 10.1016/j.jcf.2021.11.006
|
| 7 |
Adrienne P. Savant, Susanna A. McColley. Cystic fibrosis year in review 2019: Section 1 CFTR modulators. Pediatric Pulmonology 2020; 55(12): 3236 doi: 10.1002/ppul.25039
|
| 8 |
Zachary M. Sellers, David N. Assis, Shruti M. Paranjape, Meghana Sathe, Frank Bodewes, Melissa Bowen, Marco Cipolli, Dominique Debray, Nicole Green, Kara S. Hughan, William R. Hunt, Julio Leey, Simon C. Ling, Giuseppe Morelli, Daniel Peckham, Rebeca S. Pettit, Alexander Philbrick, Janis Stoll, Kay Vavrina, Stacy Allen, Tara Goodwin, Sarah E. Hempstead, Michael R. Narkewicz. Cystic fibrosis screening, evaluation, and management of hepatobiliary disease consensus recommendations. Hepatology 2024; 79(5): 1220 doi: 10.1097/HEP.0000000000000646
|
| 9 |
Mitchell L Ramsey, Michael R Wellner, Kyle Porter, Stephen E Kirkby, Susan S Li, Luis F Lara, Sean G Kelly, A James Hanje, Lindsay A Sobotka. Cystic fibrosis patients on cystic fibrosis transmembrane conductance regulator modulators have a reduced incidence of cirrhosis. World Journal of Hepatology 2022; 14(2): 411-419 doi: 10.4254/wjh.v14.i2.411
|
| 10 |
Theresa Frantzen, Sara Barsky, Geralyn LaVecchia, Michelle Marowitz, Janice Wang. Evolving Nutritional Needs in Cystic Fibrosis. Life 2023; 13(7): 1431 doi: 10.3390/life13071431
|
| 11 |
Patience Eschenhagen, Carsten Schwarz. Viele Patienten mit Mukoviszidose haben jetzt eine bessere Lebensqualität. MMW - Fortschritte der Medizin 2021; 163(S1): 74 doi: 10.1007/s15006-021-9804-z
|
| 12 |
Pawel E. Ferdek, Daria Krzysztofik, Kinga B. Stopa, Agnieszka A. Kusiak, Milena Paw, Dawid Wnuk, Monika A. Jakubowska. When healing turns into killing – the pathophysiology of pancreatic and hepatic fibrosis. The Journal of Physiology 2022; 600(11): 2579 doi: 10.1113/JP281135
|
| 13 |
Almudena Marinero Martínez-Lázaro, Rosa María Girón Moreno, Fernando Casals Seoane, Óscar Cano-Valderrama, Luisa García-Buey. Cystic fibrosis with liver involvement in adults has a benign course. Results from a tertiary referral centre cohort. Revista Española de Enfermedades Digestivas 2022; 114 doi: 10.17235/reed.2022.9289/2022
|
| 14 |
Dana-Teodora Anton-Păduraru, Alice Nicoleta Azoicăi, Felicia Trofin, Alina Mariela Murgu, Dana Elena Mîndru, Ana Simona Bocec, Codruța Olimpiada Iliescu Halițchi, Gabriela Rusu Zota, Diana Păduraru, Eduard Vasile Nastase. Diagnosis, Management, and Prognosis of Cystic Fibrosis-Related Liver Disease in Children. Diagnostics 2024; 14(5): 538 doi: 10.3390/diagnostics14050538
|
| 15 |
Robert D. Baker, Susan S. Baker. Cystic Fibrosis‐related Liver Disease. Journal of Pediatric Gastroenterology and Nutrition 2020; 71(4): 421 doi: 10.1097/MPG.0000000000002867
|
| 16 |
Leonardo Pozo, Fatimah Bello, Yamely Mendez, Salim Surani. Cystic fibrosis-related diabetes: The unmet need. World Journal of Diabetes 2020; 11(6): 213-217 doi: 10.4239/wjd.v11.i6.213
|
| 17 |
Daniel B. Karb, Linda C. Cummings. The Intestinal Microbiome and Cystic Fibrosis Transmembrane Conductance Regulator Modulators: Emerging Themes in the Management of Gastrointestinal Manifestations of Cystic Fibrosis. Current Gastroenterology Reports 2021; 23(10) doi: 10.1007/s11894-021-00817-2
|
| 18 |
Katherine A. Despotes, Scott H. Donaldson. Current state of CFTR modulators for treatment of Cystic Fibrosis. Current Opinion in Pharmacology 2022; 65: 102239 doi: 10.1016/j.coph.2022.102239
|
| 19 |
Jonathan E. M. O'Donnell, Lucy A. Hastings, Julie N. Briody, Christine L. Chan, Carla Colombo, Tonia A. Douglas, Steven D. Freedman, Tanja Gonska, Jerry R. Greenfield, Daniel H. Leung, Adeline Y. L. Lim, Antoinette Moran, Bernadette J. Prentice, Melissa S. Putman, Michael Trotter, Elizabeth Tullis, Glen P. Westall, Charles F. Verge, Claire E. Wainwright, Chee Y. Ooi. SHIFTing goals in cystic fibrosis—managing extrapulmonary disease in the era of CFTR modulator therapy; Proceedings of the International Shaping Initiatives and Future Trends (SHIFT) Symposium. Pediatric Pulmonology 2024; 59(6): 1661 doi: 10.1002/ppul.26970
|
| 20 |
Katharina Staufer. Current Treatment Options for Cystic Fibrosis-Related Liver Disease. International Journal of Molecular Sciences 2020; 21(22): 8586 doi: 10.3390/ijms21228586
|
| 21 |
Alexander J. Towbin, Wen Ye, Suiyuan Huang, Boaz W. Karmazyn, Jean P. Molleston, Prakash Masand, Daniel H. Leung, Samuel Chang, Michael R. Narkewicz, Adina L. Alazraki, A. Jay Freeman, Randolph K. Otto, Nicole Green, Ihab R. Kamel, Wikrom W. Karnsakul, John C. Magee, Jean Tkach, Joseph J. Palermo. Prospective study of quantitative liver MRI in cystic fibrosis: feasibility and comparison to PUSH cohort ultrasound. Pediatric Radiology 2023; 53(11): 2210 doi: 10.1007/s00247-023-05706-6
|
| 22 |
Marie‐Ève Bolduc, Kathryn J. Potter, Maxime Olmos, Anne Bonhoure, Adèle Coriati, Laure Alexandre‐Heymann, François Tremblay, Annick Lavoie, Maité Carricart, Peter A. Senior, Valérie Boudreau, Rémi Rabasa‐Lhoret. Cystic fibrosis‐related diabetes develops from a combination of insulin secretion defects and insulin resistance. Diabetes, Obesity and Metabolism 2024; 26(10): 4744 doi: 10.1111/dom.15844
|
| 23 |
Jordan S. Sherwood, Jagdeesh Ullal, Katherine Kutney, Kara S. Hughan. Cystic fibrosis related liver disease and endocrine considerations. Journal of Clinical & Translational Endocrinology 2022; 27: 100283 doi: 10.1016/j.jcte.2021.100283
|
| 24 |
Jérémy Dana, Dominique Debray, Aurélie Beaufrère, Sophie Hillaire, Monique Fabre, Caroline Reinhold, Thomas F. Baumert, Laureline Berteloot, Valérie Vilgrain. Cystic fibrosis-related liver disease: Clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies. Journal of Hepatology 2022; 76(2): 420 doi: 10.1016/j.jhep.2021.09.042
|
| 25 |
Michael R. Narkewicz. Cystic fibrosis liver disease in the post-modulator era. Current Opinion in Pulmonary Medicine 2023; 29(6): 621 doi: 10.1097/MCP.0000000000001017
|
| 26 |
Varinder S. Athwal, Jennifer A. Scott, Emer Fitzpatrick, Marion Rowland. Emerging clinical perspectives in cystic fibrosis liver disease. Current Opinion in Pulmonary Medicine 2021; 27(6): 593 doi: 10.1097/MCP.0000000000000824
|
| 27 |
I.M. Balfour-Lynn, J.A. King. CFTR modulator therapies – Effect on life expectancy in people with cystic fibrosis. Paediatric Respiratory Reviews 2022; 42: 3 doi: 10.1016/j.prrv.2020.05.002
|
| 28 |
Jessica A. Eldredge, Mark R. Oliver, Chee Y. Ooi. Cystic fibrosis liver disease in the new era of cystic fibrosis transmembrane conductance regulator (CFTR) modulators. Paediatric Respiratory Reviews 2024; 50: 54 doi: 10.1016/j.prrv.2023.12.005
|
| 29 |
Keyan Zarei, Mallory R. Stroik, Nick D. Gansemer, Andrew L. Thurman, Lynda S. Ostedgaard, Sarah E. Ernst, Ian M. Thornell, Linda S. Powers, Alejandro A. Pezzulo, David K. Meyerholz, David A. Stoltz. Early pathogenesis of cystic fibrosis gallbladder disease in a porcine model. Laboratory Investigation 2020; 100(11): 1388 doi: 10.1038/s41374-020-0474-8
|
| 30 |
A. G. Chermensky, T. E. Gembitskaya, A. V. Orlov, V. R. Makhmutova. The use of targeted therapy lumacaftor/ivacaftor in patients with cystic fibrosis. Meditsinskiy sovet = Medical Council 2022; (4): 98 doi: 10.21518/2079-701X-2022-16-4-98-106
|
| 31 |
Murali K. Yanda, Adi Zeidan, Liudmila Cebotaru. Ameliorating liver disease in an autosomal recessive polycystic kidney disease mouse model. American Journal of Physiology-Gastrointestinal and Liver Physiology 2023; 324(5): G404 doi: 10.1152/ajpgi.00255.2022
|
| 32 |
Frank A.J.A. Bodewes, Alvin Jay Freeman, Alexander Weymann, Dominique Debray, Isabelle Scheers, Henkjan J. Verkade, Michael R. Narkewicz. Towards a Standardized Classification of the Hepatobiliary Manifestations in Cystic Fibrosis (CFHBI): A Joint ESPGHAN/NASPGHAN Position Paper. Journal of Pediatric Gastroenterology and Nutrition 2024; 78(1): 153 doi: 10.1097/MPG.0000000000003944
|
| 33 |
Joseph J Valamparampil, Girish L Gupte. Cystic fibrosis associated liver disease in children. World Journal of Hepatology 2021; 13(11): 1727-1742 doi: 10.4254/wjh.v13.i11.1727
|
| 34 |
David Drummond, Jérémy Dana, Laureline Berteloot, Elena K. Schneider-Futschik, Frédérique Chedevergne, Céline Bailly-Botuha, Thao Nguyen-Khoa, Mathieu Cornet, Muriel Le Bourgeois, Dominique Debray, Muriel Girard, Isabelle Sermet-Gaudelus. Lumacaftor-ivacaftor effects on cystic fibrosis-related liver involvement in adolescents with homozygous F508 del-CFTR. Journal of Cystic Fibrosis 2022; 21(2): 212 doi: 10.1016/j.jcf.2021.07.018
|